TheraRadar
← Back
Data updated: Mar 29, 2026

PERRIGO PHARMA INTL

CardiovascularImmunologyGastroenterology
Specialty

PERRIGO PHARMA INTL is a specialty pharmaceutical company focused on Cardiovascular, Immunology, Gastroenterology. Key products include NASONEX 24HR ALLERGY.

2003
Since
7
Drugs
-
Trials
71
Approved (2yr)

Key Drugs

NASONEX 24HR ALLERGY
mometasone furoate
· 2022

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

DICLOFENAC SODIUM 2025-12-31
Labeling
DICLOFENAC SODIUM 2025-11-05
TRIAMCINOLONE ACETONIDE 2025-10-17
TRIAMCINOLONE ACETONIDE 2025-10-08
Labeling
DICLOFENAC SODIUM 2025-09-26
Labeling
DICLOFENAC SODIUM 2025-05-21
Labeling
LORATADINE 2025-04-25
Manufacturing (CMC)
TRIAMCINOLONE ACETONIDE 2025-04-11
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 46%
1 drugs
Immunology 46%
1 drugs
Gastroenterology 8%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

BAUSCH specialty
Immunology, Cardiovascular, Gastroenterology
Pfizer big-pharma
Immunology, Gastroenterology
Novartis big-pharma
Cardiovascular, Immunology
Merck big-pharma
Cardiovascular, Immunology
QUAGEN specialty
Gastroenterology, Cardiovascular, Immunology